Crizotinib Capsules

Crizotinib capsules are small molecule targeted therapeutic drugs with the following main indications:
For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that are positive for anaplastic lymphoma kinase (ALK).
For the treatment of patients with advanced non-small cell lung cancer (NSCLC) that are positive for ROS1.
The main ingredient of crizotinib capsules is crizotinib, a tyrosine kinase receptor inhibitor that can inhibit the signal transduction pathway of ALK gene mutant cells, thereby hindering the growth, invasion and metastasis of cancer cells, and has an anti-cancer effect.